Potentiating 1-(2-hydroxypropyl)-2-styryl-5-nitroimidazole derivatives against antibacterial agents: Design, synthesis and biology analysis

European Journal of Medicinal Chemistry

Volumn 65, Issue , 2013, Pages 456-463

  Wang, Zhong Chang ^a   Duan, Yong Tao ^a   Qin, Ya Juan ^a   Wang, Peng Fei ^a   Luo, Yin ^a   Wen, Qing ^a   Yang, Yong An ^a   Sun, Juan ^a   Hu, Yang ^a   Sang, Ya Li ^a   Zhu, Hai Liang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antibacterial activities; Cytotoxicity; FabH inhibitors; MTT assay; Nitroimidazole derivatives

Indexed keywords

1 (5 NITRO 2 STYRYL 1H IMIDAZOL 1 YL)PROPAN 2 OL; 1 [2 (2 BROMOSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [2 (2 CHLORO 6 FLUOROSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [2 (2 CHLOROSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [2 (2 FLUOROSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL)PROPAN 2 OL; 1 [2 (2 METHOXYSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL)PROPANO 2 OL; 1 [2 (2,4 DICHLOROSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL)PROPAN 2 OL; 1 [2 (3 BROMOSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [2 (3 CHLOROSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL)PROPAN 2 OL; 1 [2 (3 FLUOROSTYRYL) 5 NITRO 1HI MIDAZOL 1 YL)PROPAN 2 OL; 1 [2 (3 METHOXYSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [2 (4 BROMOSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [2 (4 CHLOROSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL)PROPAN 2 OL; 1 [2 (4 FLUOROSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL)PROPAN 2 OL; 1 [2 (4 METHOXYSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL] 2 OL; 1 [2 (4 METHYLSTYRYL) 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [2 [2 (NAPHTHALEN 2 YL)VINYL] 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [2 [4 (DIMETHYLAMINO)STYRYL] 5 NITRO 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [5 NITRO 2 (2 NITROSTYRYL) 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [5 NITRO 2 (3 NITROSTYRYL) 1H IMIDAZOL 1 YL]PROPAN 2 OL; 1 [5 NITRO 2 (4 NITROSTYRYL) 1H IMIDAZOL 1 YL]PROPAN 2 OL; 5 NITROIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACILLUS THURINGIENSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENTIATION; DRUG SYNTHESIS; ESCHERICHIA COLI; IC 50; IN VITRO STUDY; MASS SPECTROMETRY; MOLECULAR MODEL; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOMONAS AERUGINOSA; X RAY CRYSTALLOGRAPHY;

EID: 84884247676     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.05.004     Document Type: Article

References (33)

1. E.H. Patel, L.V. Paul, A. Casanueva, S. Patrick, V.R. Abratt, Overexpression of the rhamnose catabolism regulatory protein, RhaR: a novel mechanism for secnidazole resistance in Bacteroides thetaiotaomicron, J. Antimicrob. Chemoth. 64 (2009) 267-273.
2. J. Davies, Inactivation of antibiotics and the dissemination of resistance genes, Science 264 (1994) 375-382. (Pubitemid 24178900)
3. W.B. Pratt, R. Fekety, The Antimicrobial Drugs, Oxford University Press, New York, 1986, pp. 153-183. (Chapter 7).
4. M. Leeb, Antibiotics: a shot in the arm, Nature 431 (2004) 892-893.
5. C.O. Rock, J.E. Cronan, Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis, Biochim. Biophys. Acta 1302 (1996) 1-16. (Pubitemid 26267038)
6. Y. Li, Y. Luo, Y. Hu, D.D. Zhu, S. Zhang, Z.J. Liu, H.B. Gong, H.L. Zhu, Design, synthesis and antimicrobial activities of nitroimidazole derivatives containing 1,3,4-oxadiazole scaffold as FabH inhibitors, Bioorg. Med. Chem. 20 (2012) 4316-4322.
7. X. Qiu, C.A. Janson, W.W. Smith, M. Head, J. Lonsdale, A.K. Konstantinidis, Crystal structure and substrate specificity of the β-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus, J. Mol. Biol. 307 (2001) 341-356.
8. R.J. Heath, C.O. Rock, The claisen condensation in biology, Nat. Prod. Rep. 19 (2002) 581-596. (Pubitemid 35259019)
9. Z. Nie, C. Perretta, J. Lu, Y. Su, S. Margosiak, K.S. Gajiwala, J. Cortez, V. Nikulin, K.M. Yager, K. Appelt, S.S. Chu, Structure-based design, synthesis, and study of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents, J. Med. Chem. 48 (2005) 1596-1609. (Pubitemid 40364566)
10. Y. Uto, H. Nagasawa, C.Z. Jin, S. Nakayama, A. Tanaka, S. Kiyoi, H. Nakashima, M. Shimamura, S. Inayama, T. Fujiwara, Y. Takeuchi, Y. Uehara, K.L. Kirk, E. Nakata, H. Hori, Design of antiangiogenic hypoxic cell radiosensitizers: 2-Nitroimidazoles containing a 2-aminomethylene-4- cyclopentene-1,3-dione moiety, Bioorg. Med. Chem. 16 (2008) 6042-6053. (Pubitemid 351758833)
11. M.D. Crozet, P. Perfetti, M. Kaafarani, M.P. Crozet, P. Vanelle, Rapid syntheses of nitroheterocycles that bear a diethyl methylenemalonate group β to a nitro group, Org. Chem. Lett. 1 (2004) 326-330.
12. J.L. Born, B.R. Smith, N. Harper, C.J. Koch, Metabolism and radiosensitization of 4,5-dimethylmisonidazole, a ring-substituted analog of misonidazole, Biochem. Pharmacol. 43 (1992) 1337-1344.
13. A. Breccia, B. Cavalerri, G.E. Adams, Nitroimidazoles: Chemistry, Pharmacologyand Clinical Application, Plenum Press, New York, 1982.
14. L.T. Webster, A. Gilman, T.W. Rall, A.S. Nies, P. Taylor, Drugs used in the chemotherapy of protozoal infections, in: The Pharmacological Basis of Therapeutics, Pergamon Press, New York, 1990, pp. 999-1007.
15. A. Boza, R. Gonzalez, H. Novoa, D.M. Cuéllar, M. Valdés, Physico-chemical and solid- state characterization of secnidazole, IL Farmaco 55 (2000) 700-707.
16. Y. Hu, X. Lu, K. Chen, R. Yan, Q.S. Li, H.L. Zhu, Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents, Bioorg. Med. Chem. 20 (2012) 903-909.
17. J.M. Wright, L.A. Dunn, P. Upcroft, J.A. Upcroft, Efficacy of antibacterial drugs, Expert Opin. Drug Saf. 2 (2003) 529-541.
18. P. Upcroft, J.A. Upcroft, Drug targets and mechanisms of resistance in the anaerobic protozoa, Clin. Microbiol. Rev. 14 (2001) 150-164. (Pubitemid 32096211)
19. J.A. Upcroft, L.A. Dunn, J.M. Wright, K. Benakli, P. Upcroft, et al., 5-Nitroimidazole drugs effective against secnidazole-resistant Trichomonas Vaginalis and Giardia duodenalis, Antimicrob. Agents Chemother. 50 (2006) 344-347. (Pubitemid 43042942)
20. J.A. Upcroft, R.W. Campbell, K. Benakli, P. Upcroft, P. Vanelle, Efficacy of new 5-nitroimidazoles against secnidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob. Agents Chemother. 43 (1999) 73-76. (Pubitemid 29069202)
21. Y. Luo, H.Q. Li, Y. Zhou, Z.L. Li, T. Yan, H.L. Zhu, Secnidazole- deoxybenzoin derivatives as anti-helicobacter pylori agents with potent inhibitory activity against HPE induced interleukin-8, ChemMedChem 5 (2010) 1110-1116.
22. J.C. Gillis, L.R. Wiseman, Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and Bacterial vaginosis, Drugs 51 (1996) 621-638.
23. Protein Preparation Guide; Schrodinger, LLC, New York, 2007.
24. H.Ru. Tsou, N. Mamuya, B.D. Johnson, M.F. Reich, B.C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F.E. Koehn, L.M. Greenberger, Y.F. Wang, A. Wissner, 6-Substituted-4- (3-bromoph-enylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity, J. Med. Chem. 44 (2001) 2719-2734.
25. D.I. Edwards, Mechanism of antimicrobial action of secnidazole, J. Antimicrob. Chemother. 5 (1979) 499-502.
26. Bruker Analytical X-ray Systems, SMART: Bruker Molecular Analysis Research Tool, Versions 5.057 and 5.618 (1997 and 2000).
27. Bruker Analytical X-ray Systems, SAINT p NT, Versions 6.01 and 6.04 (1999 and 2001).
28. Bruker Analytical X-ray Systems, SHELXTL-NT Versions 5.10 and 6.10 (1999 and 2000).
29. H.Q. Li, L. Shi, Q.S. Li, P.G. Liu, Y. Luo, J. Zhao, H.L. Zhu, Synthesis of C(7) modified chrysin derivatives designing to inhibit β-ketoacyl-acyl carrier protein synthase III (FabH) as antibiotics, Bioorg. Med. Chem. 17 (2009) 6264-6269.
30. P. Kim, Y.M. Zhang, G. Shenoy, Q.A. Nguyen, H.I. Boshoff, U.H. Manjunatha, M.B. Goodwin, J. Lonsdale, A.C. Price, D.J. Miller, K. Duncan, S.W. White, C.O. Rock, C.E. Barry, C.S. Dowd, Structureeactivity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli, J. Med. Chem. 49 (2006) 159-171. (Pubitemid 43077329)
31. K.W. Jeong, J.Y. Lee, Y. Kim, Homology modeling and docking study of β-ketoacyl acyl carrier protein synthase III from Enterococcus Faecalis, Bull. Korean Chem. Soc. 28 (2007) 1335-1340. (Pubitemid 47360518)
32. H. Kikuchi, K. Yamamoto, S. Horoiwa, S. Hirai, R. Kasahara, N. Hariguchi, M. Matsumoto, Y. Oshima, Exploration of a new type of antimalarial compounds based on febrifugine, J. Med. Chem. 49 (2006) 4698-4706. (Pubitemid 44162697)
33. B.E. Sleebs, P.E. Czabotar, W.J. Fairbrother, W.D. Fairlie, J.A. Flygare, D.C.S. Huang, W.J.A. Kersten, M.F.T. Koehler, G. Lessene, K. Lowes, J.P. Parisot, B.J. Smith, M.L. Smith, A.J. Souers, I.P. Street, H. Yang, J.B. Baell, Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra large with potent proapoptotic cell-based activity, J. Med. Chem. 54 (2011) 1914-1926.